At the time of metastatic biopsy, 35.1% (n = 52) of patients were receiving endocrine therapy, 30.4% (n = 45) chemotherapy, and/or 8.8% (n = 13) anti-HER2 therapy for metastatic disease. This evidence concerns the gene ERBB2 and metastatic neoplasm.